SCHEMBL12925199

SCHEMBL12925199

CCN(CC)c1ccc2nc3c4ccccc4/c(=N\c4ccccn4)cc-3oc2c1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.63
MEN1 O00255 5/20 0.63
NPC1 O15118 4/20 0.63
RAB9A P51151 3/20 0.63
POLB P06746 2/20 0.63
SCP2 P22307 1/20 0.44
KDM4E B2RXH2 4/20 0.37
ALDH1A1 P00352 4/20 0.37
MAPT P10636 4/20 0.37
SMN1; SMN2 Q16637 2/20 0.37
STAT3 P40763 1/20 0.37
STAT1 P42224 1/20 0.37
HIF1A Q16665 1/20 0.37
GPR84 Q9NQS5 10/20 0.36
GRM4 Q14833 1/20 0.35
CASP1 P29466 3/20 0.33
HTT P42858 3/20 0.33
CASP7 P55210 3/20 0.33
TP53 P04637 2/20 0.33
BRCA1 P38398 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL996050 1.00 KMT2A (0.63) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL996049 1.00 KMT2A (0.63) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL13470150 0.92 NPC1 (0.56) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL996947 0.92 MEN1 (0.56) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL12925167 0.92 MEN1 (0.56) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL996949 0.92 MEN1 (0.56) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL998276 0.90 MEN1 (0.66) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL12925160 0.90 MEN1 (0.66) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL998274 0.90 MEN1 (0.66) KMT2AMEN1NPC1RAB9APOLB
SCHEMBL12925249 0.86 RAB9A (0.68) KMT2AMEN1NPC1RAB9APOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288374-B2 Medicinal composition containing benzo[a]phenoxazine compound as the active ingredient for prevention or treatment of protozoal disease HOSHI UNIVERSITY (JP) 2012-10-16 US disclosed
US-8288374-B2 Medicinal composition containing benzo[a]phenoxazine compound as the active ingredient for prevention or treatment of protozoal disease HOSHI UNIVERSITY (JP) 2012-10-16 US disclosed
US-20110021450-A1 MEDICINAL COMPOSITION CONTAINING BENZO[A]PHENOXAZINE COMPOUND AS THE ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTOZOAL DISEASE HOSHI UNIVERSITY (JP) 2011-01-27 US disclosed
US-20110021450-A1 MEDICINAL COMPOSITION CONTAINING BENZO[A]PHENOXAZINE COMPOUND AS THE ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTOZOAL DISEASE HOSHI UNIVERSITY (JP) 2011-01-27 US disclosed
EP-2269996-A1 MEDICINAL COMPOSITION CONTAINING BENZO[A]PHENOXANTHIN COMPOUND AS THE ACTIVE INGREDIENT FOR PREVENTING OR TREATING PROTOZOAL DISEASE Hoshi University (JP) 2011-01-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110021450-A1 MEDICINAL COMPOSITION CONTAINING BENZO[A]PHENOXAZINE COMPOUND AS THE ACTIVE INGREDIENT FOR PREVENTION OR TREATMENT OF PROTOZOAL DISEASE TBCA, THPO, PAOX KMT2A 1438/4885MEN1 3404/4885NPC1 2025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.